Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $709.8 million.

  • Ani Pharmaceuticals' Non-Current Assets fell 735.3% to $709.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 5673.84%. This contributed to the annual value of $756.0 million for FY2024, which is 9656.82% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Non-Current Assets is $709.8 million, which was down 735.3% from $740.4 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Non-Current Assets peaked at $766.1 million during Q3 2024, and registered a low of $279.1 million during Q3 2021.
  • Its 5-year average for Non-Current Assets is $476.9 million, with a median of $415.8 million in 2022.
  • Per our database at Business Quant, Ani Pharmaceuticals' Non-Current Assets plummeted by 1314.24% in 2021 and then skyrocketed by 10267.87% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Non-Current Assets (Quarter) stood at $449.8 million in 2021, then dropped by 7.56% to $415.8 million in 2022, then decreased by 7.51% to $384.6 million in 2023, then surged by 96.57% to $756.0 million in 2024, then fell by 6.12% to $709.8 million in 2025.
  • Its Non-Current Assets stands at $709.8 million for Q3 2025, versus $740.4 million for Q2 2025 and $756.1 million for Q1 2025.